AlloVir ($ALVR) $1M Investor Settlement
In early 2023, Allovir was accused by independent monitors of hiding that AlloVir’s Phase 3 trials for posoleucel were unlikely to succeed. When the company terminated all three trials and revealed the negative results in December 2023, $ALVR fell over 67%. By March 2024, Allovir faced a lawsuit from investors.
January 10, 2023 – Independent monitors allegedly determined that AlloVir’s Phase 3 trial for posoleucel was unlikely to succeed, but the company continued the trials without disclosure.
December 22, 2023 – AlloVir terminated all three Phase 3 trials, revealing the negative trial results. $ALVR fell over 67% on the news.
March 2024 – Investors filed a lawsuit, alleging AlloVir hid key trial failures and misled them about posoleucel’s approval chances.
February 2025 – AlloVir agreed to settle to resolve investor claims.
AlloVir is a biotech company that focused on developing posoleucel, a treatment for transplant patients vulnerable to viral infections. After promising Phase 2 results, AlloVir moved forward with three Phase 3 trials in 2022–2023.
However, internal monitoring reviews determined early on, that the trials were unlikely to succeed. Despite these warnings, AlloVir continued to promote the trials and sold millions of dollars in stock.
When the company finally announced the trial failures in December 2023, $ALVR collapsed by 67% in a single day.
By March 2024, investors sued, alleging that AlloVir misled them about the drug’s commercial prospects.
If you were affected by this situation, you may be eligible to file for a payout and receive your share of the settlement. Check the FAQ section below for details on eligibility and claims.
Frequently Asked Questions
All persons or entities who purchased AlloVir, Inc. securities between January 11, 2023 and December 21, 2023, inclusive, and were damaged thereby.
No, if you have purchased securities within the class period, you are eligible to participate.
You can participate in the settlement and retain (or sell) your securities.
The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.
The final payout amount depends on your specific trades and the number of investors participating in the settlement.
If 100% of investors file their claims - the average payout will be $0.03 per share. Although typically only 25% of investors file claims, in this case, the average recovery will be $0.12 per share.
If you're eligible, you can file your claim directly from this case page by clicking the "Collect Payout" button.
More than 100 companies are currently paying out settlements. Connect your brokerage account to automatically check which ones you may have missed — or file manually for this case.
11th.com is an investor recovery company that helps investors track and collect securities class action settlements. We will:
1. Prepare documents for your payout.
2. Audit the claim and make sure you get the maximum possible payout.
3. File a claim with the settlement administration.
4. Correspond with the settlement administration to resolve emerging issues.
5. Deliver payout directly to your brokerage account.
There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.